Zacks: Analysts Anticipate Cryoport, Inc. (NASDAQ:CYRX) Will Announce Quarterly Sales of $57.04 Million

Wall Street brokerages forecast that Cryoport, Inc. (NASDAQ:CYRXGet Rating) will post $57.04 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Cryoport’s earnings, with the highest sales estimate coming in at $60.40 million and the lowest estimate coming in at $54.20 million. Cryoport reported sales of $53.28 million in the same quarter last year, which indicates a positive year-over-year growth rate of 7.1%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Cryoport will report full-year sales of $260.00 million for the current financial year, with estimates ranging from $250.00 million to $269.16 million. For the next financial year, analysts anticipate that the business will report sales of $318.84 million, with estimates ranging from $300.00 million to $351.18 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Cryoport.

Cryoport (NASDAQ:CYRXGet Rating) last released its quarterly earnings results on Thursday, February 24th. The consumer goods maker reported ($1.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($1.17). The company had revenue of $56.44 million during the quarter, compared to analysts’ expectations of $57.61 million. Cryoport had a negative return on equity of 12.00% and a negative net margin of 123.77%. The company’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.28) EPS.

CYRX has been the subject of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $45.00 price target on shares of Cryoport in a research report on Wednesday, April 13th. TheStreet lowered Cryoport from a “c-” rating to a “d+” rating in a research report on Friday, January 28th. Roth Capital upgraded Cryoport from a “neutral” rating to a “buy” rating and set a $90.00 price target for the company in a research report on Wednesday, January 19th. SVB Leerink boosted their target price on Cryoport from $75.00 to $92.00 and gave the company an “outperform” rating in a research report on Friday, February 25th. Finally, B. Riley dropped their target price on Cryoport from $94.00 to $70.00 in a research report on Wednesday, March 2nd. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $75.14.

CYRX opened at $30.93 on Wednesday. The firm has a market cap of $1.54 billion, a P/E ratio of -5.22 and a beta of 1.07. Cryoport has a 12 month low of $26.69 and a 12 month high of $86.30. The company has a current ratio of 16.26, a quick ratio of 15.88 and a debt-to-equity ratio of 0.64. The stock has a 50-day moving average of $33.28 and a 200 day moving average of $51.63.

In other news, CFO Robert Stefanovich sold 1,095 shares of Cryoport stock in a transaction that occurred on Wednesday, March 9th. The shares were sold at an average price of $31.05, for a total transaction of $33,999.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark W. Sawicki sold 1,410 shares of Cryoport stock in a transaction that occurred on Wednesday, March 9th. The shares were sold at an average price of $31.05, for a total transaction of $43,780.50. The disclosure for this sale can be found here. Insiders have sold 5,803 shares of company stock valued at $180,183 in the last ninety days. Insiders own 9.70% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Captrust Financial Advisors raised its stake in Cryoport by 35.4% in the third quarter. Captrust Financial Advisors now owns 624 shares of the consumer goods maker’s stock worth $42,000 after buying an additional 163 shares in the last quarter. BerganKDV Wealth Management LLC increased its position in shares of Cryoport by 4.0% during the third quarter. BerganKDV Wealth Management LLC now owns 5,201 shares of the consumer goods maker’s stock worth $346,000 after purchasing an additional 200 shares in the last quarter. MML Investors Services LLC grew its holdings in shares of Cryoport by 0.7% during the fourth quarter. MML Investors Services LLC now owns 39,846 shares of the consumer goods maker’s stock valued at $2,358,000 after buying an additional 269 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Cryoport by 0.8% during the fourth quarter. Legal & General Group Plc now owns 33,982 shares of the consumer goods maker’s stock valued at $2,010,000 after buying an additional 280 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of Cryoport by 0.4% during the fourth quarter. Swiss National Bank now owns 81,100 shares of the consumer goods maker’s stock valued at $4,799,000 after buying an additional 300 shares during the last quarter.

About Cryoport (Get Rating)

Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.

Further Reading

Get a free copy of the Zacks research report on Cryoport (CYRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cryoport (NASDAQ:CYRX)

Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.